DAXAS 500mcg film-coated tablets NYCOMED ORIGINAL MEDICINE
Chemical substance: roflumilast
ATC code: R03DX07 • Respiratory system | Other systemic drugs for obstructive airway diseases
Active substance
Results for the substance roflumilast
1 result
About this active substance
Roflumilast is a selective phosphodiesterase-4 (PDE4) inhibitor used in the treatment of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis. It works by reducing inflammation in the airways, inhibiting the breakdown of cyclic adenosine monophosphate (cAMP), which leads to decreased production of pro-inflammatory cytokines.
Roflumilast is administered orally, usually once daily, and is indicated for patients with severe COPD who experience frequent exacerbations despite the use of bronchodilators. It is used as an adjunct therapy to reduce the frequency of exacerbations and improve lung function.
Common side effects include diarrhea, nausea, weight loss, and headache. In rare cases, severe adverse reactions such as psychiatric disorders or hepatotoxicity may occur. Regular monitoring of body weight and overall health is essential during treatment.
Roflumilast is a valuable therapeutic option for patients with severe COPD, helping to reduce inflammation and improve their quality of life.
Roflumilast is administered orally, usually once daily, and is indicated for patients with severe COPD who experience frequent exacerbations despite the use of bronchodilators. It is used as an adjunct therapy to reduce the frequency of exacerbations and improve lung function.
Common side effects include diarrhea, nausea, weight loss, and headache. In rare cases, severe adverse reactions such as psychiatric disorders or hepatotoxicity may occur. Regular monitoring of body weight and overall health is essential during treatment.
Roflumilast is a valuable therapeutic option for patients with severe COPD, helping to reduce inflammation and improve their quality of life.